About: Personalized vaccinology: A review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Personalized vaccinology: A review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Personalized vaccinology: A review
Creator	Kennedy, R Ovsyannikova, I Poland, G
Source	Elsevier; Medline; PMC
abstract	Abstract At the current time, the field of vaccinology remains empirical in many respects. Vaccine development, vaccine immunogenicity, and vaccine efficacy have, for the most part, historically been driven by an empiric “isolate-inactivate-inject” paradigm. In turn, a population-level public health paradigm of “the same dose for everyone for every disease” model has been the normative thinking in regard to prevention of vaccine-preventable infectious diseases. In addition, up until recently, no vaccines had been designed specifically to overcome the immunosenescence of aging, consistent with a post-WWII mentality of developing vaccines and vaccine programs for children. It is now recognized that the current lack of knowledge concerning how immune responses to vaccines are generated is a critical barrier to understanding poor vaccine responses in the elderly and in immunoimmaturity, discovery of new correlates of vaccine immunogenicity (vaccine response biomarkers), and a directed approach to new vaccine development. The new fields of vaccinomics and adversomics provide models that permit global profiling of the innate, humoral, and cellular immune responses integrated at a systems biology level. This has advanced the science beyond that of reductionist scientific approaches by revealing novel interactions between and within the immune system and other biological systems (beyond transcriptional level), which are critical to developing “downstream” adaptive humoral and cellular responses to infectious pathogens and vaccines. Others have applied systems level approaches to the study of antibody responses (a.k.a. “systems serology”), [1] high-dimensional cell subset immunophenotyping through CyTOF, [2,3] and vaccine induced metabolic changes [4]. In turn, this knowledge is being utilized to better understand the following: identifying who is at risk for which infections; the level of risk that exists regarding poor immunogenicity and/or serious adverse events; and the type or dose of vaccine needed to fully protect an individual. In toto, such approaches allow for a personalized approach to the practice of vaccinology, analogous to the substantial inroads that individualized medicine is playing in other fields of human health and medicine. Herein we briefly review the field of vaccinomics, adversomics, and personalized vaccinology.
has issue date	2018-08-28(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2017.07.062
bibo:pmid	28774561
has license	els-covid
sha1sum (hex)	8cb8963c16ddd02891876e6bb59978b38289666d
schema:url	https://doi.org/10.1016/j.vaccine.2017.07.062
resource representing a document's title	Personalized vaccinology: A review
has PubMed Central identifier	PMC5792371
has PubMed identifier	28774561
schema:publication	Vaccine
resource representing a document's body	covid:8cb8963c16ddd02891876e6bb59978b38289666d#body_text
is schema:about of	named entity 'REVIEW' named entity 'Vaccine' named entity 'programs' named entity 'field' named entity 'dose' named entity 'vaccine' named entity 'current' named entity 'PERSONALIZED' named entity 'PARADIGM' named entity 'IMMUNOSENESCENCE' named entity 'VACCINES' named entity 'ADDITION' named entity 'PREVENTABLE' named entity 'INFECTIOUS DISEASES' named entity 'VACCINE' named entity 'EMPIRICAL' named entity 'NEW' named entity 'CURRENT' named entity 'DISEASE' named entity 'OVERCOME' named entity 'HAVE' named entity 'VACCINE DEVELOPMENT' named entity 'LEVEL' named entity 'IS A' named entity 'RESPECTS' named entity 'MODEL' named entity 'BIOMARKERS' named entity 'KNOWLEDGE' named entity 'VACCINOLOGY' named entity 'THINKING' named entity 'REGARD' named entity 'PUBLIC HEALTH' named entity 'NORMATIVE' named entity 'RECENTLY' named entity 'DEVELOPING' named entity 'CRITICAL' named entity 'POOR' named entity 'CURRENT TIME' named entity 'HOW' named entity 'VACCINE EFFICACY' named entity 'CONSISTENT WITH' named entity 'DOSE' named entity 'RESPONSE' named entity 'DISCOVERY' named entity 'FIELD' named entity 'GENERATED' named entity 'BARRIER' named entity 'MENTALITY' named entity 'RESPONSES' named entity 'APPROACH' named entity 'ELDERLY' named entity 'IMMUNE RESPONSES' named entity 'PROGRAMS' named entity 'TURN' named entity 'PREVENTION OF' named entity 'AGING' named entity 'IMMUNOGENICITY' named entity 'VACCINOLOGY' named entity 'LACK' named entity 'FOR CHILDREN' named entity 'DRIVEN' named entity 'DIRECTED' named entity 'FOR THE MOST PART' named entity 'POPULATION' named entity 'UNDERSTANDING' named entity 'INJECT' named entity 'POST' named entity 'biomarkers' named entity 'disease' named entity 'paradigm' named entity 'infectious diseases' named entity 'public health' named entity 'empiric' named entity 'mentality' named entity 'correlates' named entity 'consistent' named entity 'immunogenicity' named entity 'immunogenicity' named entity 'immune responses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software